Health

Flu Season News: Ohio Reports First Child Flu Death

The latest flu season news from Ohio carries a sombre milestone for the state and a warning for families across the country. The Ohio Department of Health announced on Friday, November 20, 2026, that Ohio had reported its first flu-associated pediatric death of the 2026-27 season. The death involved a teenager under the age of 18 from Ross County, and it arrived at a moment when national flu season news was already pointing to an early and fast-moving season. Health officials in Ohio confirmed the death while urging residents to take the threat seriously, and the announcement quickly became one of the most closely watched items in health news today, because a first child death in a season is the kind of event that changes how families think about vaccination, symptoms and the weeks ahead.

Ohio typically records between one and seven flu-associated pediatric deaths in each season, according to the state health department, so a single death does not by itself define how severe the season will become. What gives this flu season news its weight is the timing and the national picture around it. The death was reported in late November, before the usual late-year rise in hospitalizations that health officials expect, and it came as the U.S. Centers for Disease Control and Prevention reported that flu activity was already climbing in many parts of the country. The department used the announcement to repeat its standing advice: everyone aged 6 months and older should receive an updated flu vaccine, and vaccination can reduce the risk of severe illness and hospitalization. That message, repeated in flu shot news every year, matters more in a season that has started early, because protection takes time to build and the virus is already circulating widely.

The Ohio announcement also underlined how uneven the season looks from state to state. The CDC currently rates Ohio's flu activity as low, even as hospitalizations generally rise toward the end of the year. A low rating for one state does not mean the virus is absent there, and it does not mean families can ignore the risk. It means that, on the measures the CDC tracks, Ohio had not yet reached the higher activity levels seen elsewhere. The first child death in the state shows that severe outcomes can occur even where overall activity is described as low, and that is why state health officials paired the announcement with a direct call for vaccination rather than treating the death as an isolated event.

Advertisement

Flu Season News: CDC Data Shows an Early and Fast-Moving Season

The national flu season news behind the Ohio report comes from CDC FluView data for the week ending November 7, 2026, published on November 13. That data showed that flu season had arrived early in the United States and was gaining speed fast. Seven states reported high or very high flu activity in that week: California, Louisiana, Oregon, South Carolina, Tennessee, Texas and Washington. That was up from two states the week before, a sharp week-to-week jump that signalled the season was accelerating rather than building slowly. Louisiana was faring the worst among the seven, and the spread across the list — from the West Coast to the South and the Pacific Northwest — showed that the early surge was not confined to one region.

The laboratory picture in the same CDC data reinforced the warning. More than 11 percent of respiratory samples tested in clinical laboratories were positive for influenza, at 11.3 percent, and nearly all of the cases stemmed from influenza A H1N1. Outpatient visits for flu-like illness were above the national baseline, another sign that the virus was already sending more people to clinics and doctors' offices than would be expected at this point in the year. Taken together, the state activity map, the test positivity rate and the outpatient visit figures painted a consistent picture in the flu season news: the season had started early, it was moving quickly, and the dominant strain was H1N1.

The season totals published by the CDC through November 7 gave the early surge a scale that is hard to ignore. Since the season began on October 1, flu had caused at least 2.6 million illnesses, 36,000 hospitalizations and 2,100 deaths, according to CDC estimates. Those figures cover only the first five weeks of the season, and they already run into the millions for illnesses and the tens of thousands for hospitalizations. Five children had died from flu this season, including two deaths reported in the past week, and the Ohio teenager became part of that wider national toll. The numbers are estimates, and they will be updated as the season continues, but they show why health news today is treating this flu season as one to watch closely rather than as a routine winter illness.

Advertisement

What Are the Symptoms of the Flu and Why Thanksgiving Matters

For families trying to make sense of flu season news, one of the first questions is what are the symptoms of the flu and how they differ from an ordinary cold. The facts in this report do not list a symptom checklist, and the important point for readers is the one health officials keep repeating: flu can cause severe illness and hospitalization, especially for children, older adults and people with underlying health conditions, and vaccination can reduce that risk. The Ohio death involved a teenager, a reminder that severe flu outcomes are not limited to the very young or the very old. When a child or teenager dies from flu, it prompts parents to look again at vaccination, at how quickly they seek care when illness appears, and at the guidance their state health department and the CDC have issued for the season.

Doctors expect the weeks ahead to test that guidance. Thanksgiving travel and gatherings are expected to help the virus spread, according to doctors cited in the reporting on the early season. The holiday brings together extended families, fills airports and highways, and puts people from different states in the same rooms for long meals and long visits. In a season that is already moving fast, that kind of mixing can accelerate transmission, and it is one reason the warning from infectious disease specialists has been so direct. Dr. Fred Lopez, an infectious diseases specialist at LSU Health Sciences Center in New Orleans, told the Associated Press: "Flu season is taking off and it's taking off in a direction that's only likely to increase in the next month or two." His advice was equally plain: "If you haven't been vaccinated, you should get vaccinated now." Louisiana, his home state, was faring the worst in the CDC data for the week ending November 7, which gives his warning a particular local weight, but the direction he described applies nationally as the season builds toward its usual late-year rise in hospitalizations.

The timing of the Ohio announcement, on Friday, November 20, just before the Thanksgiving period, makes that advice especially urgent. Families who have not yet been vaccinated still have time to act before the holiday gatherings, and the state health department's message — that everyone aged 6 months and older should receive an updated flu vaccine — is aimed squarely at that window. The vaccine does not guarantee that a person will avoid infection, and the reporting on the season does not claim otherwise. What the department said is that vaccination can reduce the risk of severe illness and hospitalization, and in a season with 36,000 hospitalizations already estimated through early November, reducing severe outcomes is the central goal of the vaccination campaign.

Advertisement

Flu Shot News: Every Strain in This Year's Vaccine Has Changed

The flu shot news for the 2026-27 season is unusual in one important respect: every strain in this year's flu shots has changed. That is a significant update to the vaccine, and it reflects the work of the FDA's advisory committee, which voted on the strains on March 12, 2026. The H3N2 piece of the vaccine was swapped to cover subclade K, a change aimed at matching the viruses expected to circulate this season. For readers following vaccine news, the strain change is a reminder that the flu vaccine is reformulated each year, and that this year's formulation is not a repeat of last year's. The decision on which strains to include is made months before the season begins, based on the best available evidence about which viruses are likely to dominate, and the March vote set the composition that is now being given in clinics across the country.

Every U.S. flu vaccine is trivalent this season, meaning it protects against three influenza viruses. That follows from the disappearance of one lineage: the B/Yamagata lineage has not been confirmed anywhere since March 2020. With that lineage no longer circulating, there is no need to include it in the vaccine, and the trivalent formulation reflects the current virology rather than a cutback in protection. The detail matters for vaccine news because it explains why the vaccine looks the way it does this year, and why the strain selection process — including the March 12 advisory committee vote — focused on the viruses that are actually in circulation, above all the H1N1 strain that now accounts for nearly all cases.

Vaccine News: The First mRNA Flu Vaccine and the mFlusiva Trial

The vaccine news this season also includes a milestone that goes beyond the annual strain update. The FDA approved the first mRNA flu vaccine, mFlusiva, in August 2026 for adults 50 and older. The approval came in two forms: traditional approval for ages 50 to 64, and accelerated approval for people 65 and older. The distinction reflects the different evidence standards applied to the two age groups, and it places mFlusiva in the history of flu vaccination as the first vaccine of its kind to use messenger RNA technology against influenza. For a public that became familiar with mRNA vaccines during the COVID-19 pandemic, the arrival of an mRNA flu vaccine is a significant development in vaccine news, and the trial evidence behind it has been closely examined.

Advertisement

A randomized trial of 40,703 participants found about 27 percent fewer laboratory-confirmed influenza cases among mFlusiva recipients than among those receiving a standard-dose flu vaccine. That is the headline result from the trial, and it is the figure that has shaped discussion of the new vaccine. The trial was large, with more than 40,000 participants, and the comparison was against a standard-dose flu vaccine rather than against no vaccination, which makes the 27 percent figure a measure of relative performance between two active vaccines. The FDA's review of that trial, and the way its findings have been described in public debate, became the subject of a fact check, as described below, and readers following FDA news should be aware that the trial result and the regulatory decision around it have both drawn scrutiny.

FDA News: The Advisory Committee, a Pulled Nomination and a Fact Check

The FDA news around this flu season is complicated by an unusual situation at the federal Advisory Committee on Immunization Practices, the body that normally issues vaccine recommendations. The committee is effectively not functioning. The Department of Health and Human Services removed its members in 2025 and appointed new ones. On March 16, 2026, a federal judge in Boston stayed those appointments and the votes the reconstituted committee had taken, leaving the committee's status in legal limbo. That sequence — removal, replacement, and a court stay — has left the normal advisory process disrupted at exactly the moment when flu season guidance matters most.

In the absence of a functioning committee, other authorities have stepped in to keep the guidance clear. On September 1, the CDC said that the flu recommendations from the July 2025 immunization schedule remain in effect for 2026-2027, which means annual flu vaccination for everyone 6 months and older. That statement preserved the standing recommendation even while the committee itself was unable to act. On September 2, the American Academy of Family Physicians, the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists and the Infectious Diseases Society of America published their own respiratory-season guidance saying the same on flu: annual flu vaccination for everyone 6 months and older. The agreement between the CDC statement and the four medical organizations gives families and clinicians a consistent message despite the disruption at the advisory committee, and it aligns with the Ohio Department of Health's own call for vaccination.

Advertisement

Related FDA politics have added another layer to the season's vaccine news. The White House pulled Dr. Heidi Overton's FDA nomination one day before a Senate committee vote, with no on-the-record explanation. Former HHS adviser Calley Means had alleged that Overton pressured former commissioner Marty Makary over mFlusiva's approval. FactCheck.org reported on November 20 that Means misrepresented the trial findings and the FDA's review. The fact check matters because it addresses the public record on the mRNA vaccine directly: the trial of 40,703 participants and the FDA's handling of it were described inaccurately, according to FactCheck.org, and the correction is part of the FDA news readers should carry into any discussion of mFlusiva. The pulled nomination itself remains unexplained on the record, and this report does not add a reason beyond what has been stated.

CDC News: COVID-19 Rising at the Same Time as Flu

The flu season news does not arrive in isolation. COVID-19 is rising at the same time, and the CDC news on that front adds to the pressure on clinics and hospitals. CDC wastewater data showed a moderate national level of viral activity in early November, with very high levels in several states including Florida, Virginia, Kentucky and Massachusetts. CDC forecasts show infections growing or likely growing in most states, which means the upward trend is expected to continue rather than level off. The combination of an early flu season and a rising COVID-19 wave is the backdrop against which health officials are urging vaccination and testing, and it is why health news today is covering both viruses together rather than treating flu as a standalone story.

The FDA's testing guidance for COVID-19 is part of that picture. The FDA recommends that people with symptoms test twice over three days, about 48 hours apart, and that people without symptoms test three times over five days. The repeated testing schedule reflects the fact that a single test can miss an infection, especially early on, and that testing more than once over several days gives a clearer answer. For families gathering for Thanksgiving, the guidance is practical as well as medical: testing, vaccination and attention to symptoms are the tools available to reduce the risk of bringing either virus to a holiday table.

Advertisement

A Recall Note and What Happens Next

There is also a brief recall note for readers to be aware of. The FDA issued a Class II recall of 8,640 boxes of Kirkland Severe Cold & Flu Plus Congestion Day and Night packs, lot numbers P139953 and P139815, with an August 2026 expiration, over quality-control issues. The product contains oral phenylephrine, which the FDA has proposed banning as an over-the-counter nasal decongestant because it is not effective. The recall is separate from the flu vaccine story, but it is relevant to flu season news because many people reaching for cold and flu remedies will see this product on shelves, and the proposed ban on oral phenylephrine reflects the FDA's view that it does not work as a nasal decongestant. Readers who have the recalled lots should follow the recall notice rather than using the product.

What happens next in this flu season will depend on how the early surge develops through the holidays and into the end of the year. Hospitalizations generally rise toward the end of the year, according to the Ohio health department's framing, and the CDC data through November 7 already showed activity climbing fast. Thanksgiving travel and gatherings are expected to help the virus spread, and the forecasts for COVID-19 point in the same direction. The Ohio death is a reminder that the season's toll is measured not only in millions of illnesses but in individual families, and the response health officials are asking for is straightforward: vaccination for everyone aged 6 months and older, attention to symptoms, and care in seeking help when illness becomes severe. The season is early, it is moving fast, and the weeks ahead will show whether the vaccination campaign and the public's response can slow a season that has already produced 2.6 million illnesses, 36,000 hospitalizations, 2,100 deaths and five child deaths before the middle of November.

Source: Reuters

Advertisement
Advertisement

Leave a Reply

Your email address will not be published. Required fields are marked *

Advertisement
Advertisement
About Us  |  Contact Us  |  Privacy Policy  |  Disclaimer  |  Terms and Conditions